SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative therapy, SCG142. This human papillomavirus (HPV) specific T cell receptor (TCR) therapy is set to be tested in a range of HPV-related solid tumors, including cervical cancer, oropharyngeal cancer, head and neck cancer, vaginal cancer, vulvar cancer, and penile cancer.
Next-Generation Chimeric Switch Receptor Enhanced TCR-T Cell Therapy
SCG142 is a potential best-in-class product, representing a next-generation advancement in chimeric switch receptor enhanced TCR-T cell therapy. The core technology, proprietary to SCG, utilizes the GianTCR technology platform to successfully screen and isolate natural high affinity HPV specific TCRs. These are then combined with chimeric switch receptors, resulting in a therapy that can significantly enhance T cell proliferation ability and tumor inhibition compared to traditional TCR-T cell therapies.
Specific Tumor Killing Effects and Improved Efficacy
SCG142 has demonstrated specific tumor killing effects on various tumors, including those related to HPV-16 and HPV-52 genotypes, which are commonly associated with cervical cancer. The therapy’s ability to target and eliminate cancer cells with precision makes it a promising candidate for the treatment of HPV-related cancers, offering a potentially more effective and targeted approach to therapy.-Fineline Info & Tech
